Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0

被引：1
|
作者：
Vairetti, Mariapia [1 ]
Colucci, Giuseppe [2 ]
Ferrigno, Andrea [1 ]
机构：
[1] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy
[2] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Div Gastroenterol & Hepatol, I-20122 Milan, Italy
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 14期
关键词：
STEATOSIS; MODEL; DIET; ACID;
D O I：
10.3390/ijms23147894
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Metformin for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Farah, Samira
    Thu Nguyen
    Kelsberg, Gary
    Safranek, Sarah
    AMERICAN FAMILY PHYSICIAN, 2019, 99 (04) : 262 - 263
  • [42] Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan
    Okanoue, Takeshi
    Umemura, Atsushi
    Yasui, Kohichiroh
    Itoh, Yoshito
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 153 - 162
  • [43] Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation
    Carter, Danielle
    Dieterich, Douglas T.
    Chang, Charissa
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 213 - +
  • [44] Galectin-3 (Gal-3) Expression in Relation to Fibrosis in Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
    Goodman, Zachary D.
    Mulder, Christopher
    Bolduc, Caroline A.
    Raines, Matthew F.
    Cebe, Katherine M.
    Alaparthi, Lakshmi
    Monge, Fanny
    Traber, Peter G.
    Harrison, Stephen A.
    GASTROENTEROLOGY, 2014, 146 (05) : S951 - S951
  • [45] The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis
    Sharma, Mithun
    Mitnala, Shasikala
    Vishnubhotla, Ravi K.
    Mukherjee, Rathin
    Reddy, Duvvur N.
    Rao, Padaki N.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2015, 5 (02) : 147 - 158
  • [46] Nonalcoholic Fatty Liver disease (NAFLD)
    Zeuzem, S.
    Trautwein, C.
    GASTROENTEROLOGE, 2020, 15 (02): : 77 - 77
  • [47] NONALCOHOLIC FATTY LIVER DISEASE AND STEATOHEPATITIS
    Colak, Yasar
    Tuncer, Ilyas
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2010, 73 (03): : 85 - 91
  • [48] Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
    Murphy, William A.
    Adiwidjaja, Jeffry
    Sjostedt, Noora
    Yang, Kyunghee
    Beaudoin, James J.
    Spires, Jessica
    Siler, Scott Q.
    Neuhoff, Sibylle
    Brouwer, Kim L. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (02) : 275 - 297
  • [49] High Risk of Mortality and Disease Progression Associated with Diabetes Mellitus (DM) and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) in Medicare Patients
    Loomba, Rohit
    Fraysse, Jeremy
    Li, Suying
    Ozbay, A. Burak
    DIABETES, 2019, 68
  • [50] Clinical Utility of a Noninvasive Metabolic Approach in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in Type 2 Diabetes
    Bellido, Virginia
    Martinez-Arranz, Ibon
    Goicolea, Ignacio
    Amor, Antonio J.
    Pi, Javier
    Perez, Antonio
    Espiga, Javier
    Montalban, Coral
    Mayo, Rebeca
    Gaztambide, Sonia
    DIABETES, 2020, 69
12345